<DOC>
	<DOCNO>NCT01084668</DOCNO>
	<brief_summary>The aim post-marketing observational study ( PMOS ) obtain data long-term safety , efficacy , quality life outcome adalimumab routine clinical use participant moderate severe chronic plaque psoriasis unsustainable clinical response biologic disease modify anti-rheumatic drug ( BDMARDs ) . There data far show effect switch BDMARDs adalimumab patient moderate severe chronic plaque psoriasis . This study design evaluate long-term effectiveness adalimumab participant moderate severe chronic plaque psoriasis use Psoriasis Area Severity Index ( PASI ) participants previously treat efalizumab , infliximab , etanercept either never achieve satisfactory response , achieve satisfactory response initially lose time , discontinue treatment due intolerance/side effect ( ) reason , example regular stop etanercept .</brief_summary>
	<brief_title>Quality Life Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs</brief_title>
	<detailed_description>This non-interventional PMOS conduct prospective , single-country , multicenter format ass quality life psoriasis patient take adalimumab prescribed physician accordance term local marketing authorization regard dose , population , indication . The prescription adalimumab clearly separate decision include participant study . No procedure standard care perform . Visits non-interventional timing participant appointment leave physician . After therapy initiation , visit occur 12 month usually close Weeks 4 , 12 , 24 , 36 , 52 total 6 visit ( Visits 1 6 include Screening ) . Because participant visit leave physician , participant failure meet suggest visit week constitute breach protocol .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients adalimumab therapy indicate prescribed accord product label Patients age 18 year old Unsatisfactory response prior BDMARDS ( efalizumab , infliximab , etanercept ) patient moderate severe chronic plaque psoriasis achievement satisfactory response initially , loss time discontinuation treatment due intolerance/side effect ( ) reason e.g . restart regular stop etanercept Patients must fulfill Austrian Treatment Recommendations use BDMARD psoriasis ( chest Xray purify protein derivative [ PPD ] skin test negative tuberculosis ) Patient willing consent data collect provided Abbott Patient must able willing selfadminister Pen injection qualify person available administer Pen injection Patients meet contraindication outline late version HumiraPen Summary Product Characteristics ( SPC ) Patients meet criterion use BDMARDs Austrian Treatment Recommendations Patients participate another study clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>moderate severe chronic plaque psoriasis</keyword>
	<keyword>adalimumab</keyword>
	<keyword>Psoriasis Area Severity Index ( PASI )</keyword>
	<keyword>Disease Life Quality Index ( DLQI )</keyword>
	<keyword>Nail Psoriasis Severity Index ( NAPSI )</keyword>
	<keyword>biologic disease modify anti-rheumatic drug ( BDMARD )</keyword>
	<keyword>antibody</keyword>
	<keyword>monoclonal</keyword>
</DOC>